CASI Pharmaceuticals (CASI) Competitors

Neoleukin Therapeutics (NASDAQ:NLTX) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Do institutionals and insiders believe in NLTX or CASI?

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is NLTX or CASI more profitable?

Neoleukin Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. Neoleukin Therapeutics' return on equity of -37.22% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%

Which has higher earnings & valuation, NLTX or CASI?

CASI Pharmaceuticals has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	-7.46
CASI Pharmaceuticals	$22.06M	2.19	-$26.94M	-$2.23	-1.40

Which has more volatility & risk, NLTX or CASI?

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Do analysts rate NLTX or CASI?

CASI Pharmaceuticals has a consensus price target of $6.00, suggesting a potential upside of 92.31%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to NLTX or CASI?

In the previous week, CASI Pharmaceuticals had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for CASI Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. CASI Pharmaceuticals' average media sentiment score of 1.87 beat Neoleukin Therapeutics' score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
CASI Pharmaceuticals	Very Positive

Does the MarketBeat Community favor NLTX or CASI?

CASI Pharmaceuticals received 150 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 50.25% of users gave CASI Pharmaceuticals an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.

Company	Underperform	Outperform
Neoleukin Therapeutics	Outperform Votes 50 45.87%	Underperform Votes 59 54.13%
CASI Pharmaceuticals	Outperform Votes 200 50.25%	Underperform Votes 198 49.75%

Summary

CASI Pharmaceuticals beats Neoleukin Therapeutics on 12 of the 17 factors compared between the two stocks.